Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: A case report

Blood Transfusion

Volumn 11, Issue 2, 2013, Pages 311-314

  Gueli, Angela ^a,b   Gottardi, Daniela ^a   Hu, Huijing ^a   Ricca, Irene ^c   De Crescenzo, Alberto ^a   Tarella, Corrado ^a,b  

^a MAURIZIANO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Department of Orthopaedic Surgery   (Italy)

Author keywords

Bendamustine; Cold agglutinin disease; Haemolytic anaemia; Non Hodgkin's lymphoma

Indexed keywords

BENDAMUSTINE; BILIRUBIN; BLOCKING ANTIBODY; CISPLATIN; COMPLEMENT COMPONENT C3D; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDARABINE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; OXALIPLATIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; UROBILINOGEN; VINCRISTINE;

AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; CAUCASIAN; COOMBS TEST; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HEMOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIMODALITY CANCER THERAPY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; HUMANS; IMMUNOLOGIC FACTORS; MALE; NITROGEN MUSTARD COMPOUNDS;

EID: 84876930558     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0166-12     Document Type: Article

References (22)

1. Dacie JV, Crookston JH, Christenson WN. Incomplete cold antibodies role of complement in sensitization to antiglobulin serum by potentially haemolytic antibodies. Br J Haematol 1957;3:77-87.
2. Gertz MA. Cold agglutinin disease. Haematol J 2006;91:439-41.
3. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J 1981;282:2023-7. (Pubitemid 11117667)
4. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004;103:2925-8. (Pubitemid 38451661)
5. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematol J 2006;91:460-6.
6. Berentsen S, Randen U, Vagan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 2010;116:3180-4.
7. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002;29(4 Suppl. 13):27-32. (Pubitemid 34857895)
8. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-9.
9. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23. (Pubitemid 40223656)
10. Machover D, Delmas-Marsalet B, Misra SC, et al. Dexamethasone, high-dose cytarabine and oxaliplatin (DHAOX) as salvage tratment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol 2001;12:1439-43. (Pubitemid 33100251)
11. Chau I, Webb A, Cunningham D, et al. An oxaliplatinbased chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001, 115:786-92. (Pubitemid 34042894)
12. Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymph 2008;49:1074-80. (Pubitemid 351943252)
13. Ruella M, Ricca I, Gueli A, et al. Dexamethasone, cytarabine and cisplatin or oxaliplatin schedule (DHAP or OxDHA) is effective and widely applicable in chronic lymphocytic leukaemia and Waldenstrom macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 2009;114:3434.
14. Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am J Hematol 1996;53:279-80. (Pubitemid 26419723)
15. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603-13. (Pubitemid 46844778)
16. Tarella C, Zanni M, Magni M, et al. Rituximab improves the therapeutic efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter GITIL survey of 745 patients. J Clin Oncol 2008;26:3166-75.
17. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149-69. (Pubitemid 351406218)
18. Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med 2011;22:220-9.
19. Forero-Torres A, Saleh MN. Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. Clin Lymphoma Myeloma. 2007;8(Suppl. 1):S13-7. (Pubitemid 351204446)
20. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-17. (Pubitemid 351378007)
21. Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol 2011;48(Suppl. 1):S24-36.
22. Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011;153:309-17.